Perspective Therapeutics, Inc. CATX 深 沪
等待开盘 10-06 09:30:00 美东时间
2.565
-0.185
-6.73%
华盛通- 最 高3.37
- 今 开2.75
- 成交量 355.37万股
- 最 低 2.44
- 昨 收 2.75
- 总市值 0
- 52周最高 6.16
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 1.955
- 委 比 -70.74%
- 总股本 --
- 历史最高 26.02
- 量 比 2.44
- 振 幅 33.82%
- 历史最低 0.12
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
10-02 23:47
Perspective Therapeutics Receives European Commission Orphan Designation For VMT-α-NET To Treat Gastroenteropancreatic Neuroendocrine Tumors
The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).Orphan medicinal product designation by the EC may provide certain development
07-28 18:42
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Earnings Scheduled For March 16, 2026
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) stock rose 80.4% to $4.15 during Thursday'...
01-30 01:05
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
<p>Perspective Therapeutics announced two presentations at the 2025 SNMMI Annual Meeting, focusing on their radiopharmaceutical assets. The first study on [212Pb]VMT-α-NET demonstrated feasible dosimetry using [203Pb]VMT-α-NET as an imaging surrogate and highlighted the need for further clinical observations. The second study on [68Ga]PSV377 showed strong tumor uptake in a preclinical model and promising first-in-human imaging results in metastatic colorectal cancer.</p>
2025-06-21 12:00
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
<p> Recent interim results from Perspective Therapeutics' Phase 1/2a trial of [212Pb]VMT-α-NET in patients with neuroendocrine tumors (NETs) show favorable safety and efficacy. Among 42 patients, no dose-limiting toxicities or discontinuations were observed. In Cohort 2, four patients experienced objective responses, three confirmed and持久。Seven patients remain progression-free after over a year of follow-up. Perspective plans a conference call on June 2, 2025, to discuss these data. </p>
2025-05-30 21:21
Truist Securities Initiates Coverage On Perspective Therapeutics with Buy Rating, Announces Price Target of $21
Truist Securities analyst Nicole Germino initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and announces Price Target of $21.
2024-09-25 23:06
Cantor Fitzgerald Reiterates Overweight on Perspective Therapeutics
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
2024-09-06 22:10
